NiCE Announces Elite Partners of the Year Awards at Interactions 2025, Driving Worldwide Acceleration of CX Automation
This year's honorees played a pivotal role in accelerating CXone Mpower adoption and scaling the impact of customer service automation globally
HOBOKEN, N.J., June 18, 2025--(BUSINESS WIRE)--NiCE (Nasdaq: NICE) today announced the winners of the NiCE Elite Partners of the Year award at Interactions 2025, the industry's largest customer experience event, taking place in Las Vegas. The winning partners were recognized for their exceptional contributions to expanding CXone Mpower's global footprint, enabling more organizations to deliver connected, proactive and automated customer service.
Selected for their commitment to deepening expertise through advanced certifications and delivering differentiated value to customers, the winners exemplify excellence in innovation, execution, and impact. The winners of the NiCE Elite Partners of the Year award are:
Top Global System Integrator – For redefining customer service as a catalyst for proactive growth and delivering seamless, data-driven, and intuitive experiences at scale, the winner is Accenture.
Top Technology Solution Distributor - For expanding the reach of NiCE's solutions by activating a robust network of technology advisors and accelerating momentum across the channel, the winner is Telarus.
Top Carrier Communication Partner – For delivering the connectivity, reliability, and security essential to supporting AI-powered customer experiences at scale, the winner is Verizon.
Top CALA Partner – For showcasing exceptional regional leadership and expertise in advancing CXone Mpower adoption throughout CALA and enabling enterprises to harness the power of next-generation CX automation, the winner is Betta.
Top Canada Partner – For advancing CX innovation in the Canadian market through major infrastructure investments and market leadership in communications and media, the winner is Bell Canada.
Top Public Sector Partner – For enabling government and public service agencies to transform workforce and HR operations through CXone Mpower-driven innovation, the winner is Deloitte GPS.
Top Trusted Advisor – For serving as a strategic partner to clients navigating cloud, cybersecurity, and automation solutions, and helping organizations modernize and elevate the customer experience, the winner is Amplix.
Top DEVone Partner – For redefining real-time collaboration by enabling businesses to instantly add co-browsing and collaborative capabilities to any digital experience and helping over 3,000 organizations streamline customer interactions, the winner is Surfly.
Top Certified Implementation Partner – For delivering seamless CXone Mpower implementations with precision and speed, and helping enterprises across industries drive agility, resilience, and transformation through expert guidance and execution, the winner is Tech Mahindra.
Top Technology Partner – For empowering innovation through globally trusted cloud infrastructure and enabling organizations to deploy AI-powered experiences at speed and scale, the winner is AWS.
Barry Cooper, President, CX Division, NiCE, said, "CXone Mpower is setting a new global standard for AI-driven customer service. It's our partners who help bring this innovation to life, extending our reach, accelerating adoption, and driving measurable outcomes for businesses worldwide. We're proud to recognize this year's winners for their outstanding dedication, expertise, and role in reshaping the future of customer experience."
About NiCENiCE (NASDAQ: NICE) is transforming the world with AI that puts people first. Our purpose-built AI-powered platforms automate engagements into proactive, safe, intelligent actions, empowering individuals and organizations to innovate and act, from interaction to resolution. Trusted by organizations throughout 150+ countries worldwide, NiCE's platforms are widely adopted across industries connecting people, systems, and workflows to work smarter at scale, elevating performance across the organization, delivering proven measurable outcomes.
Trademark Note: NiCE and the NiCE logo are trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE's marks, please see: www.nice.com/nice-trademarks.
Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the "Company"). In some cases, such forward-looking statements can be identified by terms such as "believe," "expect," "seek," "may," "will," "intend," "should," "project," "anticipate," "plan," "estimate," or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in general economic and business conditions; competition; successful execution of the Company's growth strategy; success and growth of the Company's cloud Software-as-a-Service business; rapid changes in technology and market requirements; the implementation of AI capabilities in certain products and services, decline in demand for the Company's products; inability to timely develop and introduce new technologies, products and applications; difficulties in making additional acquisitions or difficulties or effectively integrating acquired operations; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company's dependency on third-party cloud computing platform providers, hosting facilities and service partners; cyber security attacks or other security incidents; privacy concerns; changes in currency exchange rates and interest rates, the effects of additional tax liabilities resulting from our global operations, the effect of unexpected events or geo-political conditions, including those arising from political instability or armed conflict that may disrupt our business and the global economy; our ability to recruit and retain qualified personnel; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the "SEC"). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company's reports filed from time to time with the SEC, including the Company's Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618356904/en/
Contacts
Corporate Media Contact Christopher Irwin-Dudek, +1 201 561 4442, media@nice.com, ET
Investors Marty Cohen, +1 551 256 5354, ir@nice.com, ETOmri Arens, +972 3 763 0127, ir@nice.com, CET
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 minutes ago
- Business Wire
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, 'Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy,' from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. 'These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia,' said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. 'We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year.' 'It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events,' said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. 'As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future.' About Type 1 Diabetes T1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About Zimislecel Zimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading 'Risk Factors' in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website.
Yahoo
an hour ago
- Yahoo
Rocket Lab Stock Soars Ahead of High-Stakes Launch
Rocket Lab (NASDAQ:RKLB) shares climbed about 6% on Friday, boosted by optimism around its upcoming mission and strong contract momentum. Warning! GuruFocus has detected 7 Warning Signs with MSTR. The company plans to launch its next Electron rocket, dubbed Symphony In The Stars, on June 20 from its New Zealand site. The flight is one of two missions awarded by a private commercial client, adding to confidence in Rocket Lab's ability to secure repeat business on accelerated timelines. Market watchers often view timely launch execution as a sign of operational strength. Rocket Lab's growing cadence of missions has helped build investor confidence, particularly among retail traders, who tend to rally around launches with the potential to support future revenue streams. Analysts have pointed to the company's financial performance as another driver of sentiment. For the first quarter of 2025, Rocket Lab reported revenue of around $122.6 million, marking a year-over-year increase of more than 30%. Though the firm remains in investment mode, investors are focusing on top-line growth and expansion into adjacent offerings such as spacecraft components and orbital services. Technical indicators ahead of the launch may have contributed to the rally, alongside a broader uptick in space-related stocks. The small-satellite launch sector continues to attract interest from both government and commercial players, with Rocket Lab seen as one of the more active names in the segment. Shares were last up around 6% in afternoon trading, tracking toward their highest level in over a month. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Analyst Confidence Grows as Semtech (SMTC) Expands IoT Footprint
Semtech Corporation (NASDAQ:SMTC) is one of the 11 Best Tech Stocks to Buy On the Dip. On May 28, Analyst Christopher Rolland of Susquehanna reiterated a Buy rating on Semtech Corporation (NASDAQ:SMTC) with a price target of $60. The rating comes after the company released its fiscal first-quarter results for 2026. The company reported net sales of $251.1 million, reflecting a 22% year-over-year increase. The analyst noted that the company has demonstrated resilience with its core products FiberEdge and TriEdge by filling the gap caused by a temporary slowdown in its CopperEdge product line. This product diversification supports ongoing growth, with new applications expected to ramp up in the latter half of the year. Moreover, Semtech Corporation (NASDAQ:SMTC)'s LoRa technology, which is central to its IoT strategy, has exceeded expectations. The company is actively pursuing new opportunities in the expanding IoT sector, noted Christopher Rolland. Despite short-term challenges such as the NVIDIA ACC disappointment, the company remains focused on reducing debt and investing in research and development. A technician looking at a circuit board of analog semiconductor products. Semtech Corporation (NASDAQ:SMTC) is a high-performance semiconductor company that provides advanced technology solutions. It operates through three main areas including Signal Integrity, Analog Mixed Signal and Wireless, and IoT Systems and Connectivity. While we acknowledge the potential of SMTC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
